DelveInsight’s, “Cushing’s Syndrome - Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Cushing’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Cushing’s Syndrome: Overview
Cushing’s disease is considered a rare condition characterized by the hypersecretion of the adrenocorticotropic hormone (ACTH) due to a pituitary adenoma that ultimately causes endogenous hypercortisolism by stimulating the adrenal glands. It’s also known as hypercortisolism. The clinical signs suggesting Cushing’s disease, such as obesity, moon face, hirsutism, and facial plethora. Endogenous hypercortisolism is associated with an increased risk of cardiovascular and metabolic manifestations, as well as respiratory disorders, psychiatric complications, osteoporosis and infections, leading to high rates of morbidity and mortality. Signs and symptoms of Cushing's syndrome vary. People who have very high levels of cortisol for a long time are likely to have clear signs of the disorder, including: weight gain, thin arms and legs, a round face, increased fat around the base of the neck, a fatty hump between the shoulders, wide purple stretch marks, mainly on the abdomen, breasts, hips, and under the arms and weak muscles
Children with Cushing’s syndrome tend to have obesity and grow more slowly than other children. Women may have excess hair on their face, neck, chest, abdomen, and thighs. Menstrual periods may become irregular or stop. Men may have decreased fertility with lowered interest in sex and may have erectile dysfunction.
"Cushing Syndrome- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cushing Syndrome pipeline landscape is provided which includes the disease overview and Cushing Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cushing Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Cushing Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cushing Syndrome Emerging Drugs
Relacorilant: Corcept Therapeutics
Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator that does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushing’s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents, as well as orphan drug designation in the United States for the treatment of pancreatic cancer and both the United States and the European Union for the treatment of Cushing’s syndrome.
SPI-62: Sparrow Pharmaceuticals
SPI-62 is an oral, small molecule, novel 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor. Sparrow’s lead proprietary small molecule SPI-62 reduces intracellular cortisol, the main cause of morbidity in Cushing syndrome. SPI-62 was associated with few, mostly mild, adverse effects in four prior clinical trials. In subjects with diabetic peripheral neuropathy, SPI-62 showed clinically meaningful separation from placebo on HbA1c, glucose, cholesterol, and triglycerides.
CRN04894: Crinetics Pharmaceuticals
CRN04894 is a nonpeptide, small molecule that is designed to be taken orally to block the interaction of ACTH with its target receptor. It has the potential to offer a life-saving treatment option to patients with Cushing’s disease, CAH and related diseases. Based on encouraging preclinical results, Company initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.
Further product details are provided in the report……..
This segment of the report provides insights about the different Cushing Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cushing Syndrome
There are approx. 8+ key companies which are developing the therapies for Cushing Syndrome. The companies which have their Cushing Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Corcept Therapeutics.
Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
Route of Administration
Cushing Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cushing’s Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cushing’s Syndrome drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Cushing Syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cushing Syndrome – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Relacorilant: Corcept Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SPI-62: Sparrow Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CRN-04894: Crinetics Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Cushing Syndrome Key Companies
Cushing Syndrome Key Products
Cushing Syndrome- Unmet Needs
Cushing Syndrome- Market Drivers and Barriers
Cushing Syndrome- Future Perspectives and Conclusion
Cushing Syndrome Analyst Views
Cushing Syndrome Key Companies
Appendix
List of Table
Table 1: Total Products for Cushing’s Syndrome
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Cushing’s Syndrome
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Strongbridge Biopharma
• Corcept Therapeutics
• Crinetics Pharmaceuticals
• Cyclacel Pharmaceuticals
• Sparrow Pharmaceuticals
• AstraZeneca